The Russian Ministry of Health has registered the first Russian biosimilar of natalizumab

The Russian Ministry of Health has registered the first domestic analogue of the drug natalizumab, used to treat adult patients with highly active forms of remitting multiple sclerosis. This was reported by the press service of Generium, the company that developed the drug.

Natalizumab was approved in the USA in 2004 and registered in Russia in 2010.

"Natalizumab has taken an important place in the global practice of treating multiple sclerosis and is indicated for patients with severe disease. The first Russian biosimilar is a new therapeutic option that expands patients' access to highly effective treatment of multiple sclerosis in Russia," said Daniil Talyansky, CEO of Generium JSC.

Natalizumab is a monoclonal antibody that blocks the receptors of immune cells, thus preventing their migration through the blood-brain barrier into the central nervous system and preventing the inflammatory process underlying damage and destruction of the myelin sheaths of neurons.

All important news is on the Izvestia channel in the MAX messenger.